Pharmacological chaperones for human α-N-acetylgalactosaminidase.

Pharmacological chaperones for human α-N-acetylgalactosaminidase.

Schindler/Kanzaki disease is an inherited metabolic disease with no current treatment options. This neurologic disease results from a defect in the lysosomal α-N-acetylgalactosaminidase (α-NAGAL) enzyme. In this report, we show evidence that the iminosugar DGJNAc can inhibit, stabilize, and chaperon...

Full description

Bibliographic Details
Main Authors:	Clark, N, Metcalf, M, Best, D, Fleet, G, Garman, S
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Synthesis of 2-acetamido-1,2-dideoxy-d-galacto-nojirimycin [DGJNAc] from d-glucuronolactone: the first sub-micromolar inhibitor of α-N-acetylgalactosaminidases
by: Best, D, et al.
Published: (2010)

The Effect of Fucoidan from the Brown Alga Fucus evanescence on the Activity of α-N-Acetylgalactosaminidase of Human Colon Carcinoma Cells
by: Irina Bakunina, et al.
Published: (2018-05-01)

shRNA-mediated downregulation of α-N-Acetylgalactosaminidase inhibits migration and invasion of cancer cell lines
by: Ehsan Saburi, et al.
Published: (2017-09-01)

Schistosoma mansoni α-N-acetylgalactosaminidase (SmNAGAL) regulates coordinated parasite movement and egg production.
by: Benjamin J Hulme, et al.
Published: (2022-01-01)

The EngCP endo α-N-acetylgalactosaminidase is a virulence factor involved in Clostridium perfringens gas gangrene infections
by: Jackie K. Cheung, et al.
Published: (2020-02-01)

Synthesis of 2-acetamido-1,2-dideoxy-D-galacto-nojirimycin [DGJNAc] from D-glucuronolactone: the first sub-micromolar inhibitor of alpha-N-acetylgalactosaminidases
by: Best, D, et al.
Published: (2010)

Effects of Sponge-Derived Alkaloids on Activities of the Bacterial α-<span style="font-variant: small-caps">D-</span>Galactosidase and Human Cancer Cell α-N-Acetylgalactosaminidase
by: Natalia Utkina, et al.
Published: (2021-05-01)

Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase
by: Roberta Iacono, et al.
Published: (2021-01-01)

Effect of Phlorotannins from Brown Algae <i>Costaria costata</i> on α-<i>N</i>-Acetylgalactosaminidase Produced by Duodenal Adenocarcinoma and Melanoma Cells
by: Irina Bakunina, et al.
Published: (2022-12-01)

Mechanistic Insights into Dibasic Iminosugars as pH-Selective Pharmacological Chaperones to Stabilize Human α‑Galactosidase
by: Huang-Yi Li, et al.
Published: (2024-02-01)

Galactosemia: Towards Pharmacological Chaperones
by: Samantha Banford, et al.
Published: (2021-02-01)

Looking-glass synergistic pharmacological chaperones: DGJ and L-DGJ from the enantiomers of tagatose.
by: Jenkinson, S, et al.
Published: (2011)

Pharmacological Chaperone Therapy for Pompe Disease
by: Marc Borie-Guichot, et al.
Published: (2021-11-01)

Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.
by: Wang, G, et al.
Published: (2012)

Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease
by: Kato, A, et al.
Published: (2016)

Pharmacological Chaperones Attenuate the Development of Opioid Tolerance
by: Youta Okuyama, et al.
Published: (2020-10-01)

Second-Generation Pharmacological Chaperones: Beyond Inhibitors
by: My Lan Tran, et al.
Published: (2020-07-01)

Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat
by: Hila Braunstein, et al.
Published: (2020-10-01)

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
by: Pedro Besada, et al.
Published: (2021-12-01)

CSPα—Chaperoning Presynaptic Proteins
by: Julien eDonnelier, et al.
Published: (2014-04-01)

Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
by: Wang, G, et al.
Published: (2009)

Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection
by: Mikhail V. Voronin, et al.
Published: (2023-01-01)

Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones
by: Charles Sutton, et al.
Published: (2022-05-01)

Alchemical Design of Pharmacological Chaperones with Higher Affinity for Phenylalanine Hydroxylase
by: María Conde-Giménez, et al.
Published: (2022-04-01)

Functional Rescue of Inactivating Mutations of the Human Neurokinin 3 Receptor Using Pharmacological Chaperones
by: Ross C. Anderson, et al.
Published: (2022-04-01)

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study
by: Correra Antonella, et al.
Published: (2010-12-01)

Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity
by: Patricia René, et al.
Published: (2021-02-01)

4-Hexylresorcinol: pharmacologic chaperone and its application for wound healing
by: Seong-Gon Kim
Published: (2022-02-01)

Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion protein
by: Amar Nath Gupta, et al.
Published: (2016-06-01)

NACHO Engages N-Glycosylation ER Chaperone Pathways for α7 Nicotinic Receptor Assembly
by: Hae-Jin Kweon, et al.
Published: (2020-08-01)

Targeted stabilization of Munc18‐1 function via pharmacological chaperones
by: Debra Abramov, et al.
Published: (2021-01-01)

Chaperone-Mediated Autophagy in Neurodegenerative Diseases: Molecular Mechanisms and Pharmacological Opportunities
by: Yi-Ting Wang, et al.
Published: (2022-07-01)

Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology
by: Daniela Grasso, et al.
Published: (2023-03-01)

Chemical chaperones exceed the chaperone effects of RIC-3 in promoting assembly of functional α7 AChRs.
by: Alexander Kuryatov, et al.
Published: (2013-01-01)

The influence of the N-terminal region proximal to the core domain on the assembly and chaperone activity of αB-crystallin
by: Jovcevski, B, et al.
Published: (2018)

Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
by: Trapero, A, et al.
Published: (2012)

Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests
by: Cammisa Marco, et al.
Published: (2011-10-01)

Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach
by: Gioena Pampalone, et al.
Published: (2021-12-01)

Pharmacological targeting of host chaperones protects from pertussis toxin in vitro and in vivo
by: Katharina Ernst, et al.
Published: (2021-03-01)

In vivo substrates of the lens molecular chaperones αA-crystallin and αB-crystallin.
by: Usha P Andley, et al.
Published: (2014-01-01)